Waiting for the changes after the adoption of steatotic liver disease

Clin Mol Hepatol. 2023 Sep 6. doi: 10.3350/cmh.2023.0291. Online ahead of print.ABSTRACTSteatotic liver disease was suggested as an overarching term encompassing various etiologies of hepatic steatosis. Experts from multinational liver societies went through the Delphi process, including four rounds of surveys, and consented to adopt a new nomenclature and definition instead of the conventional nonalcoholic fatty liver disease. This was to improve the understanding of the patients and primary care physicians, with an explanation of the pathophysiology in the name of the disease. Also, it could minimize the stigmatization of patients by using the histological neutral term "steatosis" instead of "fatty". Herein, we will discuss the changes and continuity between the two nomenclatures, MASLD and NAFLD, as well as the challenges to MASLD which need to be addressed in future.PMID:37670441 | DOI:10.3350/cmh.2023.0291
Source: Clinical and molecular hepatology - Category: Gastroenterology Authors: Source Type: research